PDS Biotechnology Unveils Promising Flu Vaccine Data

The latest update is out from PDS Biotechnology ( (PDSB) ).

On May 8, 2025, PDS Biotechnology Corporation announced updates on preclinical immune response data for its novel Infectimune® based flu vaccine, presented at the IMMUNOLOGY2025™ Annual Meeting. The studies, conducted by NIAID’s CIVR-HRP, demonstrated that Infectimune® elicited a significantly greater frequency of multifunctional, influenza-specific CD4 T cells and protective antibodies against multiple strains of influenza compared to current vaccines. This development highlights the potential of Infectimune® as a promising option in universal flu vaccine development, allowing PDS Biotech to focus resources on its immuno-oncology programs.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers with its investigational targeted immunotherapy Versamune® HPV, which is being developed in combination with a standard-of-care immune checkpoint inhibitor.

Average Trading Volume: 638,834

Technical Sentiment Signal: Sell

Current Market Cap: $54.35M

See more data about PDSB stock on TipRanks’ Stock Analysis page.